Literature DB >> 7954788

Pharmaceutical research in molecular oncology.

J B Gibbs1, A Oliff.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7954788     DOI： 10.1016/0092-8674(94)90189-9

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


× No keyword cloud information.
  19 in total

1.  A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission.

Authors:  A J Bardwell; L J Flatauer; K Matsukuma; J Thorner; L Bardwell
Journal:  J Biol Chem       Date:  2000-12-28       Impact factor: 5.157

Review 2.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

3.  The development of alkylphosphocholines as signal transduction inhibitors: experimental and clinical challenges.

Authors:  P Hilgard; J Pohl; J Engel
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 4.  Kinase packing defects as drug targets.

Authors:  Alejandro Crespo; Ariel Fernández
Journal:  Drug Discov Today       Date:  2007-10-30       Impact factor: 7.851

Review 5.  The cellular basis of metastasis.

Authors:  P Ruiz; U Günthert
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 6.  Growth factors in bladder cancer.

Authors:  M Liebert
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 7.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 8.  Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls.

Authors:  J Rak; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 9.  Cell and molecular mechanisms of pathogenesis and treatment of cancer.

Authors:  D A Rew
Journal:  Postgrad Med J       Date:  1998-02       Impact factor: 2.401

10.  An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.

Authors:  Ariel Fernández; Angela Sanguino; Zhenghong Peng; Eylem Ozturk; Jianping Chen; Alejandro Crespo; Sarah Wulf; Aleksander Shavrin; Chaoping Qin; Jianpeng Ma; Jonathan Trent; Yvonne Lin; Hee-Dong Han; Lingegowda S Mangala; James A Bankson; Juri Gelovani; Allen Samarel; William Bornmann; Anil K Sood; Gabriel Lopez-Berestein
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.